KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Non-Current Assets (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of Non-Current Assets data on record, last reported at $502.1 million in Q4 2025.

  • For Q4 2025, Non-Current Assets rose 101.29% year-over-year to $502.1 million; the TTM value through Dec 2025 reached $1.3 billion, up 59.76%, while the annual FY2025 figure was $502.1 million, 101.29% up from the prior year.
  • Non-Current Assets reached $502.1 million in Q4 2025 per ACAD's latest filing, up from $254.3 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $502.1 million in Q4 2025 and bottomed at $76.8 million in Q3 2021.
  • Average Non-Current Assets over 5 years is $164.8 million, with a median of $141.8 million recorded in 2023.
  • Peak YoY movement for Non-Current Assets: soared 252.55% in 2021, then decreased 2.95% in 2022.
  • A 5-year view of Non-Current Assets shows it stood at $82.3 million in 2021, then dropped by 2.95% to $79.9 million in 2022, then surged by 66.3% to $132.8 million in 2023, then skyrocketed by 87.79% to $249.4 million in 2024, then surged by 101.29% to $502.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $502.1 million in Q4 2025, $254.3 million in Q3 2025, and $265.0 million in Q2 2025.